Skip to main content
Premium Trial:

Request an Annual Quote

Nanogen Closes $7.7M Acquisition of Spectral Diagnostics Cardiac Test Business

NEW YORK, Feb. 7 (GenomeWeb News) - Nanogen today said it has closed its acquisition of Spectral Diagnostics' rapid cardiac immunoassay test business, originally announced in December.


Total cost for the deal was CDN$9 million ($7.7 million), comprising CDN$5.65 million in cash and CDN$3.35 million in Nanogen common shares, Nanogen said.


Nanogen will now assume sales, marketing, and manufacturing activities for the Cardiac Status, Decision Point, and i-Lynx reader product lines.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge is weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.